Genocea Biosciences Inc (NASDAQ:GNCA) CEO William D. Clark acquired 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 17th. The shares were acquired at an average cost of $0.80 per share, with a total value of $20,000.00. Following the purchase, the chief executive officer now directly owns 82,931 shares of the company’s stock, valued at approximately $66,344.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Genocea Biosciences Inc (GNCA) traded up $0.01 during mid-day trading on Friday, reaching $0.82. The company’s stock had a trading volume of 1,447,500 shares, compared to its average volume of 1,162,675. The company has a debt-to-equity ratio of 2.51, a quick ratio of 1.55 and a current ratio of 1.55. Genocea Biosciences Inc has a 52-week low of $0.79 and a 52-week high of $7.29. The company has a market capitalization of $23.54, a price-to-earnings ratio of -0.38 and a beta of 1.94.
Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by ($0.08). During the same period in the previous year, the company earned ($0.45) earnings per share. equities analysts expect that Genocea Biosciences Inc will post -1.91 earnings per share for the current fiscal year.
Several equities research analysts recently issued reports on the company. ValuEngine lowered Genocea Biosciences from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 26th. Cowen reissued a “buy” rating and set a $10.00 price objective on shares of Genocea Biosciences in a research note on Tuesday, September 26th. Needham & Company LLC lowered Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, September 26th. Zacks Investment Research lowered Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Finally, Stifel Nicolaus lowered Genocea Biosciences from a “buy” rating to a “hold” rating and dropped their price objective for the company from $15.00 to $2.50 in a research note on Monday, September 25th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $6.25.
TRADEMARK VIOLATION NOTICE: “Genocea Biosciences Inc (GNCA) CEO William D. Clark Acquires 25,000 Shares” was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2018/01/19/genocea-biosciences-inc-gnca-ceo-william-d-clark-acquires-25000-shares.html.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.